-
-
-
-
-
-
-
This digital health stock is ready to re-rate higher: Goldman
-
-
-
-
-
-
-
ResMed (RMD) PT Lowered to $286 at Morgan Stanley
-
-
-
-
-
-
-
Needham Reiterates Hold Rating on ResMed (RMD)
-
-
-
-
-
-
-
Goldman Sachs Adjusts APAC Director's Cut Names in December Update
-
-
-
-
-
-
-
KeyBanc Reiterates Overweight Rating on ResMed (RMD)
-
-
-
-
-
-
-
ResMed (RMD) Tops Q4 EPS by 7c
-
-
-
-
-
-
-
ResMed (RMD:AU) (RMD) PT Raised to AUD45 at Citi, Removes 90-Day Downside Catalyst Watch
-
451,554 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

